Literature DB >> 6432904

The murine IL 2 receptor. II. Monoclonal anti-IL 2 receptor antibodies as specific inhibitors of T cell function in vitro.

T R Malek, G Ortega, J P Jakway, C Chan, E M Shevach.   

Abstract

We assessed the dependency of a variety of immune responses for IL 2 in vitro by using anti-IL 2 receptor monoclonal antibodies as specific inhibitors of IL 2 function. The generation of allogeneic cytotoxic T lymphocyte (CTL) responses and maximal thymocyte proliferation to phytohemagglutinin (PHA) and IL 1 was readily susceptible to inhibition by these antibodies. Furthermore, the IL 2 receptor-positive, IL 2-responsive cell in the CTL cultures expressed killer cell activity. A greater variability in susceptibility to anti-IL 2 receptor antibody inhibition was noted for proliferation of T cells to concanavalin A, PHA, or allogeneic cells. Under certain conditions, however, each of these responses was almost completely inhibited. In most instances, the failure to block a response could be accounted for by either high levels of endogenous IL 2 production or high density of cell surface IL 2 receptors, which represent two known variables that influence the level of inhibition by these antibodies. Analysis of IL 2 receptor expression by mitogen-stimulated T cells suggested that accessory cells may play a role in the optimal expression of the IL 2 receptor. These experiments demonstrate that IL 2 is the predominant growth factor by which T lymphocytes proliferate, but do not exclude the possibility of an IL 2-independent pathway for growth.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6432904

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  24 in total

1.  Phenotypic evolution of CTL B-lines in vitro.

Authors:  M Février; C Foa; J Simonetti; C Prevot; M Barad; M Berebbi
Journal:  Br J Exp Pathol       Date:  1987-04

2.  Use of the CH lymphomas as models of murine B cell differentiation.

Authors:  G A Bishop; G Haughton
Journal:  Immunol Res       Date:  1986       Impact factor: 2.829

3.  Functional heterogeneity in the process of T lymphocyte activation; barium blocks several modes of T cell activation, but spares a functionally unique subset of PHA-activable T cells.

Authors:  L T Peçanha; G A Dos Reis
Journal:  Clin Exp Immunol       Date:  1989-05       Impact factor: 4.330

4.  Antigen-dependent and -independent proliferative T-cell populations in the peritoneal exudate cells of immunized mice.

Authors:  T Nitta; K Nemoto; H Yabuta; S Okumura; M Nakano
Journal:  Immunology       Date:  1989-04       Impact factor: 7.397

5.  Effects of anti-Tac antibody on the response of large granular lymphocytes to interleukin-2.

Authors:  N Mukaida; T Kasahara; J Hosoi; K Shioiri-Nakano; T Kawai
Journal:  Immunology       Date:  1986-01       Impact factor: 7.397

6.  Activation and proliferation of normal resting human T lymphocytes in serum-free culture: role of IL-4 and IL-6.

Authors:  D Habetswallner; E Pelosi; D Bulgarini; A Camagna; P Samoggia; E Montesoro; G Giannella; D Lazzaro; G Isacchi; U Testa
Journal:  Immunology       Date:  1988-11       Impact factor: 7.397

7.  Requirements for activation of CD8+ murine T cells. I. Development of cytolytic activity.

Authors:  D C Cronin; D W Lancki; F W Fitch
Journal:  Immunol Res       Date:  1994       Impact factor: 2.829

Review 8.  Regulation of lymphocyte growth by antagonists of interleukin-2 or its cellular receptor.

Authors:  G N Gaulton; J F Markmann
Journal:  Immunol Res       Date:  1988       Impact factor: 2.829

9.  Recombinant interleukin 2 regulates levels of c-myc mRNA in a cloned murine T lymphocyte.

Authors:  J C Reed; D E Sabath; R G Hoover; M B Prystowsky
Journal:  Mol Cell Biol       Date:  1985-12       Impact factor: 4.272

10.  Therapy with monoclonal antibody to interleukin 2 receptor spares suppressor T cells and prevents or reverses acute allograft rejection in rats.

Authors:  J W Kupiec-Weglinski; T Diamantstein; N L Tilney; T B Strom
Journal:  Proc Natl Acad Sci U S A       Date:  1986-04       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.